Medtech Insight is highlighting awareness for mental health, Alzheimer’s and brain health by speaking with industry leaders about rising innovations to address neurological diseases and mental health, the regulatory and investment climate, reimbursement, and more.
Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s Patients – Study
Firm’s Is One Of Several FDA-Designated Breakthroughs Aiming To Outshine Drug Treatments
In a pilot study building on previously published Phase 2 trial results, Sinaptica’s precision therapy, combining repetitive transcranial magnetic stimulation with EEG monitoring and artificial intelligence, showed macro- and micro-structural grey matter preservation and increased functional connectivity in Alzheimer’s patients versus a sham treatment arm.
